Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome.
Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distres
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.